<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989166</url>
  </required_header>
  <id_info>
    <org_study_id>28664</org_study_id>
    <nct_id>NCT04989166</nct_id>
  </id_info>
  <brief_title>The Effect of Nano-curcumin Supplementation in Acute Pancreatitis</brief_title>
  <official_title>The Effect of Nano-curcumin Supplementation on Clinical Symptoms and Signs, Length of Hospital Stays and Inflammation Level in Moderate Acute Pancreatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to investigate the effect of Nano-curcumin supplementation on clinical&#xD;
      symptoms and signs, length of hospital stay and inflammation level in moderate acute&#xD;
      pancreatitis. 42 eligible patients with moderate acute pancreatitis will randomly assign to&#xD;
      consume two soft gels each containing 40 mg of Nano-curcumin or placebo (control group) every&#xD;
      morning and evening for two weeks. Both groups will also receive the standard medical&#xD;
      treatment in hospital. Patients' blood samples will be taken before and after the&#xD;
      intervention to determine complete blood count (CBC), kidney and liver function, blood sugar,&#xD;
      electrolytes and C-reactive protein (CRP). Clinical signs during the hospitalization period&#xD;
      will be recorded and the two groups will also be compared in terms of local complications and&#xD;
      length of hospital stay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dietary intake of patients will be examined by two non-consecutive 24-hour food recalls at&#xD;
      the beginning and end of the study. Patient's weight (kg) and Body Mass Index (BMI) will also&#xD;
      be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
    <description>Admission days in hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum CRP level</measure>
    <time_frame>2 weeks</time_frame>
    <description>serum C-reactive protein level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Nano-curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80mg of Nano-curcumin daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nano-curcumin</intervention_name>
    <description>Nano-curcumin soft gels</description>
    <arm_group_label>Nano-curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a clinical diagnosis of moderate acute pancreatitis (specifically, a&#xD;
             history of acute abdominal pain associated with a greater than threefold elevation of&#xD;
             the serum amylase and/or computed tomographic evidence of acute pancreatitis)&#xD;
             presenting within 72 hours of onset of pain&#xD;
&#xD;
          -  Age range of 18-75&#xD;
&#xD;
          -  having the ability to intake soft gels orally&#xD;
&#xD;
          -  lack of Pregnancy or breastfeeding&#xD;
&#xD;
          -  lack of any history of allergy to Curcumin&#xD;
&#xD;
          -  Patients with no acute exacerbation of chronic pancreatitis&#xD;
&#xD;
          -  lack of prior antioxidant therapy&#xD;
&#xD;
          -  lack of severe co-morbid illness (liver disease including cirrhosis and hepatitis,&#xD;
             Renal failure (Cl Cr &lt;30))&#xD;
&#xD;
          -  lack of active gastrointestinal ulcers&#xD;
&#xD;
          -  not to take anticoagulants such as heparin, Clopidogrel, Dipyridamole, Warfarin and&#xD;
             Ticlopidine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient's unwillingness to continue cooperating&#xD;
&#xD;
          -  Patients who have not consumed more than 20% of soft gels&#xD;
&#xD;
          -  The diagnosis of the treating physician based on the termination of the patient's&#xD;
             participation in the study&#xD;
&#xD;
          -  Incidence of side effects due to supplementation in the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Azita Hekmatdoost, MD.phD</last_name>
    <phone>+982122357484</phone>
    <email>a_hekmat2000@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Nutrition and Food Technology Research Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

